SCHEMBL3556975

SCHEMBL3556975

CCOC(=O)COC(c1cccc(F)c1-c1cccc(C)c1)[C@@H]1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
REN P00797 3/20 0.52
KAT6A Q92794 2/20 0.41
KAT5 Q92993 2/20 0.41
USP30 Q70CQ3 2/20 0.40
GPR119 Q8TDV5 6/20 0.40
BTK Q06187 1/20 0.38
KAT7 O95251 2/20 0.37
KAT8 Q9H7Z6 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 1/20 0.37
ACKR3 P25106 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3556972 1.00 REN (0.52) RENKAT6AKAT5USP30GPR119
SCHEMBL3571302 0.88 REN (0.59) RENKAT6AKAT5USP30GPR119
SCHEMBL3571861 0.88 REN (0.57) RENKAT6AKAT5USP30GPR119
SCHEMBL3569063 0.88 REN (0.59) RENKAT6AKAT5USP30GPR119
SCHEMBL3571858 0.88 REN (0.57) RENKAT6AKAT5USP30GPR119
SCHEMBL3569058 0.88 REN (0.59) RENKAT6AKAT5USP30GPR119
SCHEMBL3569061 0.88 REN (0.59) RENKAT6AKAT5USP30GPR119
SCHEMBL5616624 0.88 REN (0.49) RENKDM4EALDH1A1HPGD
SCHEMBL3605920 0.87 GPR119 (0.46) RENUSP30GPR119BTKKAT7
SCHEMBL13502914 0.87 GPR119 (0.46) RENUSP30GPR119BTKKAT7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO claimed
US-7858624-B2 Piperidine and morpholine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-12-28 US disclosed
US-7858624-B2 Piperidine and morpholine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-12-28 US disclosed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
WO-2007117560-A2 PIPERIDINE AND MORPHOLINE RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 REN 1/4885KAT6A 4428/4885KAT5 4181/4885
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors REN, ACE, PREP REN 1/4885KAT6A 2746/4885KAT5 3064/4885
US-20090264428-A1 Renin Inhibitors REN, ACE, SERPINB1 REN 1/4885KAT6A 4029/4885KAT5 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.